About: The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
Creator	Borisevich, Viktoriya Bavari, Sina Soloveva, Veronica Hur, Sun Cadena, Cristhian Haridas, Viraga Nambu, Aya Ranjbar, Shahin Sadukhan, Supriya Cassell, Gail Geisbert, Thomas Goldfeld, Anne Jasenosky, Luke Mire, Chad
Source	PMC
abstract	Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial antiviral signaling protein, interferon regulatory factor 3, and interferon activities and induces transcription of the antiviral phosphatase GADD34. NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein's ability to block RIG-I and PKR sensing of EBOV. NTZ also inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through RIG-I and GADD34, but not PKR, consistent with VSV's distinct host innate immune evasion mechanisms. Thus, NTZ counteracts varied virus-specific immune evasion strategies by generally enhancing the RNA sensing and interferon axis that is triggered by foreign cytoplasmic RNA exposure, and holds promise as an oral therapy against EBOV.
has issue date	2019-08-08(xsd:dateTime)
bibo:doi	10.1016/j.isci.2019.07.003
bibo:pmid	31402258
has license	cc-by-nc-nd
sha1sum (hex)	af0442df28de9051b460e903b513afc2a13b54a4
schema:url	https://doi.org/10.1016/j.isci.2019.07.003
resource representing a document's title	The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
has PubMed Central identifier	PMC6831822
has PubMed identifier	31402258
schema:publication	iScience
resource representing a document's body	covid:af0442df28de9051b460e903b513afc2a13b54a4#body_text
is schema:about of	named entity 'DRUG' named entity 'Nitazoxanide' named entity 'Ebola' named entity 'Information' named entity 'Virus' named entity 'SUPPLEMENTAL' named entity 'FDA' named entity 'EBOLA VIRUS' named entity 'ORAL' named entity 'HOST' named entity 'INFORMATION' named entity 'ANTIVIRAL' named entity 'APPROVED' named entity 'RESPONSES' named entity 'NITAZOXANIDE' named entity 'crispr' named entity 'cyclophilin A' named entity 'protein' named entity '0.01' named entity 'GADD34' named entity 'plasmid' named entity 'infection' named entity 'RIG-I' named entity 'plaque forming units' named entity 'inocula' named entity 'CMV' named entity 'GAPDH' named entity 'RIG-I' named entity 'DMEM' named entity 'DMEM' named entity 'transfection' named entity 'gRNA' named entity 'A549' named entity 'GADD34' named entity '37°C' named entity '37°C' named entity 'Supp' named entity 'Supernatants' named entity 'CRISPR' named entity 'recombinant' named entity 'EBOV' named entity 'infection' named entity 'plaque assay' named entity 'cDNA' named entity 'pFLAG' named entity 'assay' named entity 'A549' named entity 'Zaire ebolavirus' named entity 'virus' named entity 'GADD34' named entity 'IFN-β' named entity 'genomic sequence' named entity 'RNA' named entity 'CRISPR' named entity 'virus' named entity 'CRISPR' named entity 'Kikwit' named entity 'A549' named entity 'supernatants' named entity 'plaque assay' named entity 'gene expression' named entity 'GADD34' named entity 'CRISPR' named entity 'adsorbed' named entity 'EBOV' named entity 'A549 cell' named entity 'supernatants' named entity 'ng/mL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software